검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 21일
현재 선택: 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | Ixekizumab | Anti-IL17 |
Overview Company | Eli Lilly and Company | Prof. Dr. Stephan Weidinger |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | Psoriatic Arthritis | Atopic Dermatitis |
Overview Indication | Psoriasis; Atopic Dermatitis | Atopic Dermatitis; Psoriasis |
Overview Phase | APPROVED | PRECLINICAL |
Overview Status | RECRUITING | RECRUITING |
MoA Mechanism | targets and signaling pathway | targeting the IL-17A pathway |
MoA Biomarker | — | biomarker of immunosuppression |
PK/PD Half-life | 13 h | — |
PK/PD Species | Mouse | Hamster |
PK/PD Animal (cat.) | Mouse | Unknown |
PK/PD Experiment | pharmacokinetic | PD |
Toxicology Species | Mouse | Hamster |
Toxicology Animal (cat.) | Mouse | Unknown |
Toxicology Major finding | Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et al.. We appreciate the interest of Joaquin et al in our recent study on the treatment persistence of ixekizumab in psoriatic arthritis. In response, we clarify that our study utilized prospectively collected real-world clinical data from a multicenter observational cohort, rather than administrative databases. We empha… | PDE4 inhibition in pediatric psoriasis: analysis of the SPROUT study on apremilast.. Moderate-to-severe plaque psoriasis in the pediatric population represents a complex therapeutic challenge. Although the advent of biologic drugs (anti-TNF, anti-IL17) has revolutionized efficacy standards, there remains an unmet need for oral, safe therapeutic options that do not require regular monitoring. Aprem… |
Clinical Data Tier / Score | S · 42 | C · 21 |
Clinical Program phase | APPROVED | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 9일 (12일 전) | 2026년 7월 13일 (9일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 21일
현재 선택: 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||
|---|---|---|
Overview Program | Ixekizumab | Anti-IL17 |
Overview Company | Eli Lilly and Company | Prof. Dr. Stephan Weidinger |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | Psoriatic Arthritis | Atopic Dermatitis |
Overview Indication | Psoriasis; Atopic Dermatitis | Atopic Dermatitis; Psoriasis |
Overview Phase | APPROVED | PRECLINICAL |
Overview Status | RECRUITING | RECRUITING |
MoA Mechanism | targets and signaling pathway | targeting the IL-17A pathway |
MoA Biomarker | — | biomarker of immunosuppression |
PK/PD Half-life | 13 h | — |
PK/PD Species | Mouse | Hamster |
PK/PD Animal (cat.) | Mouse | Unknown |
PK/PD Experiment | pharmacokinetic | PD |
Toxicology Species | Mouse | Hamster |
Toxicology Animal (cat.) | Mouse | Unknown |
Toxicology Major finding | Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et al.. We appreciate the interest of Joaquin et al in our recent study on the treatment persistence of ixekizumab in psoriatic arthritis. In response, we clarify that our study utilized prospectively collected real-world clinical data from a multicenter observational cohort, rather than administrative databases. We empha… | PDE4 inhibition in pediatric psoriasis: analysis of the SPROUT study on apremilast.. Moderate-to-severe plaque psoriasis in the pediatric population represents a complex therapeutic challenge. Although the advent of biologic drugs (anti-TNF, anti-IL17) has revolutionized efficacy standards, there remains an unmet need for oral, safe therapeutic options that do not require regular monitoring. Aprem… |
Clinical Data Tier / Score | S · 42 | C · 21 |
Clinical Program phase | APPROVED | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 9일 (12일 전) | 2026년 7월 13일 (9일 전) |
추천 비교
추천 비교